{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:44:49Z","timestamp":1786985089211,"version":"build-2736575974"},"reference-count":101,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.beem.2026.102098","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:40:05Z","timestamp":1773765605000},"page":"102098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation and management of metabolic-associated chronic kidney disease"],"prefix":"10.1016","volume":"40","author":[{"given":"Sunita","family":"Bavanandan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2026.102098_bib1","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"GBD 2023 Chronic Kidney Disease Collaborators","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2026.102098_bib2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.kint.2025.03.034","article-title":"Metabolic disorder\u2013associated kidney disease and diabetic kidney disease in developing countries","volume":"108","author":"Bavanandan","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.beem.2026.102098_bib3","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00125-022-05713-6","article-title":"Low- and middle-income countries demonstrate rapid growth of type 2 diabetes: an analysis based on Global Burden of Disease 1990\u20132019 data","volume":"65","author":"Liu","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.beem.2026.102098_bib4","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2026.102098_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.kint.2025.01.044","article-title":"Metabolic dysfunction\u2013associated kidney disease: pathogenesis and clinical manifestations","volume":"108","author":"Bansal","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.beem.2026.102098_bib6","series-title":"USRDS Annual Data Report: Epidemiology of kidney disease in the United States","article-title":"Chapter 11: International Comparisons in 2024","author":"United States Renal Data System","year":"2024"},{"key":"10.1016\/j.beem.2026.102098_bib7","unstructured":"International Diabetes Federation. IDF Diabetes Atlas 11th Edition- 2025, available at diabetesatlas.org."},{"issue":"7","key":"10.1016\/j.beem.2026.102098_bib8","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/dme.13324","article-title":"Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies","volume":"34","author":"Koye","year":"2017","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.beem.2026.102098_bib9","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2337\/dc15-1536","article-title":"Diabetes in Asia and the Pacific: implications for the global epidemic","volume":"39","author":"Nanditha","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2026.102098_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240971","article-title":"Prevalence of metabolic syndrome among adult population in India: a systematic review and meta-analysis","volume":"15","author":"Krishnamoorthy","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2026.102098_bib11","doi-asserted-by":"crossref","first-page":"7841","DOI":"10.1038\/s41598-020-64884-7","article-title":"Association between serum uric acid and metabolic syndrome: a cross-sectional study in Bangladeshi adults","volume":"10","author":"Ali","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.beem.2026.102098_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1749-6632.2012.06838.x","article-title":"Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations","volume":"1281","author":"Gujral","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.beem.2026.102098_bib13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/nyas.12098","article-title":"Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States","volume":"1281","author":"Ma","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.beem.2026.102098_bib14","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"4S","key":"10.1016\/j.beem.2026.102098_bib15","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"issue":"13","key":"10.1016\/j.beem.2026.102098_bib16","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2026.102098_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2215\/CJN.0000000857","article-title":"A Real-World Cohort Study of the risks of kidney failure and death in diabetes","volume":"21","author":"Tuttle","year":"2026","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.beem.2026.102098_bib18","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.beem.2026.102098_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/nep.70030","article-title":"Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease - 2025 Update","volume":"30","author":"Liew","year":"2025","journal-title":"Nephroogy"},{"key":"10.1016\/j.beem.2026.102098_bib20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00125-021-05590-5","article-title":"Kidney outcomes and all-cause mortality in people with type 2 diabetes exhibiting non-albuminuric kidney insufficiency","volume":"65","author":"Yamamoto","year":"2022","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.beem.2026.102098_bib21","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1681\/ASN.2010010063","article-title":"Comparison of different measures of urinary protein excretion for prediction of renal events","volume":"21","author":"Heerspink","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.beem.2026.102098_bib22","unstructured":"ISN-KDIGO CKD Early Identification & Intervention Toolkit. Available at \u3008https:\/\/www.theisn.org\/initiatives\/toolkits\/ckd-earlyscreening-intervention\u3009."},{"key":"10.1016\/j.beem.2026.102098_bib23","doi-asserted-by":"crossref","first-page":"426","DOI":"10.7326\/M20-0529","article-title":"Conversion of urine protein creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis","volume":"173","author":"Sumida","year":"2020","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.beem.2026.102098_bib24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1681\/ASN.2004060447","article-title":"Performance of the modification of diet in renal disease and cockcroft-gault equations in the estimation of GFR in health and in chronic kidney disease","volume":"6","author":"Poggio","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.beem.2026.102098_bib25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2026.102098_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/biom15010041","article-title":"The metabolism of creatinine and its usefulness to evaluate kidney function and body composition in clinical practice","volume":"15","author":"\u00c1vila","year":"2025","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.beem.2026.102098_bib27","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.semnephrol.2021.06.002","article-title":"The renal pathology of obesity: structure-function correlations","volume":"41","author":"Tsuboi","year":"2021","journal-title":"Semin Nephrol"},{"issue":"2","key":"10.1016\/j.beem.2026.102098_bib28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2015.18202","article-title":"Multinational assessment of accuracy of equations for predicting risk of kidney failure: a metaanalysis","volume":"315","author":"Tangri","year":"2016","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.beem.2026.102098_bib29","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.2337\/dc22-0698","article-title":"Development and validation of prediction models of adverse kidney outcomes in the population with and without diabetes","volume":"45","author":"Grams","year":"2022","journal-title":"Diabetes Care"},{"issue":"ement 1","key":"10.1016\/j.beem.2026.102098_bib30","article-title":"#2546 CKD-PC risk model for CKD progression: validation and association with outcomes in the FIDELITY population","volume":"39","author":"Shafi","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.beem.2026.102098_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae052","article-title":"Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population","volume":"17","author":"Tangri","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.beem.2026.102098_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000519920","article-title":"Clinical utility of KidneyIntelX in early stages of diabetic kidney disease in the CANVAS trial","volume":"53","author":"Lam","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.beem.2026.102098_bib33","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"AHA SCIENTIFIC STATEMENT. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2026.102098_bib34","article-title":"Enhancing cardiovascular risk prediction in Asian populations: a machine learning approach integrated with digital health platforms","volume":"27","author":"Kassim","year":"2025","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"issue":"1","key":"10.1016\/j.beem.2026.102098_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/eurjpc\/zwac176","article-title":"Including Measures of Chronic Kidney Disease to Improve Cardiovascular Risk Prediction by SCORE2 and SCORE2-OP","volume":"30","author":"Matsushita","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.beem.2026.102098_bib36","first-page":"1","article-title":"KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD)","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","journal-title":"Kidney Int Suppl"},{"issue":"1S","key":"10.1016\/j.beem.2026.102098_bib37","first-page":"S1","article-title":"KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)","volume":"109","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2026","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.beem.2026.102098_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.arrt.2003.10.007","article-title":"Is obesity a major cause of chronic kidney disease?","volume":"11","author":"Hall","year":"2004","journal-title":"Adv Ren Replace Ther"},{"issue":"8","key":"10.1016\/j.beem.2026.102098_bib39","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrneph.2016.75","article-title":"Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis","volume":"12","author":"D\u2019Agati","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1016\/j.beem.2026.102098_bib40","first-page":"512","article-title":"The podocyte as a direct target for metabolic injury","volume":"89","author":"Mallipattu","year":"2016","journal-title":"Kidney Int"},{"issue":"17","key":"10.1016\/j.beem.2026.102098_bib41","first-page":"1566","article-title":"Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial","volume":"170","author":"Look AHEAD Research Group","year":"2010","journal-title":"Arch Intern Med"},{"issue":"9403","key":"10.1016\/j.beem.2026.102098_bib42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"World Health Organisation Expert Consultation","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.beem.2026.102098_bib43","article-title":"Use of unregulated weight-loss and antidiabetic products promoted via social media in South and Southeast Asia: public health implications","volume":"7","author":"Mishra","year":"2022","journal-title":"BMJ Glob Health"},{"issue":"3","key":"10.1016\/j.beem.2026.102098_bib44","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease","volume":"99","author":"KDIGO Blood Pressure Work Group","year":"2021","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.beem.2026.102098_bib45","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1159\/000500042","article-title":"Fruit and vegetable treatment of chronic kidney disease-related metabolic acidosis reduces cardiovascular risk better than sodium bicarbonate","volume":"49","author":"Goraya","year":"2019","journal-title":"Am J Nephrol"},{"issue":"7","key":"10.1016\/j.beem.2026.102098_bib46","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1681\/ASN.2015040369","article-title":"Ketoanalogue-supplemented vegetarian very low\u2013protein diet and CKD progression","volume":"27","author":"Garneata","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"23","key":"10.1016\/j.beem.2026.102098_bib47","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1001\/jama.2008.808","article-title":"Effect of a low\u2013glycemic index or a high\u2013cereal fiber diet on type 2 diabetes: a randomized trial","volume":"300","author":"Jenkins","year":"2008","journal-title":"J Am Med Assoc"},{"issue":"7383","key":"10.1016\/j.beem.2026.102098_bib48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/482027a","article-title":"Public health: the toxic truth about sugar","volume":"482","author":"Lustig","year":"2012","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.beem.2026.102098_bib49","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beem.2026.102098_bib50","first-page":"259","article-title":"KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease","volume":"3","author":"KDIGO Lipid Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"10.1016\/j.beem.2026.102098_bib51","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2215\/CJN.06190616","article-title":"Healthy dietary patterns and risk of chronic kidney disease: a systematic review and meta-analysis of cohort studies","volume":"12","author":"Kelly","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.beem.2026.102098_bib52","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2215\/CJN.06080809","article-title":"Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease","volume":"5","author":"Kalantar-Zadeh","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.beem.2026.102098_bib53","first-page":"1445","article-title":"Exercise training in chronic kidney disease patients","volume":"45","author":"Howden","year":"2015","journal-title":"Sports Med"},{"issue":"9","key":"10.1016\/j.beem.2026.102098_bib54","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"20","key":"10.1016\/j.beem.2026.102098_bib55","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"Renoprotective effect of the angiotensin-converting\u2013enzyme inhibitor captopril in diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.beem.2026.102098_bib56","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.beem.2026.102098_bib57","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.beem.2026.102098_bib58","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"issue":"9176","key":"10.1016\/j.beem.2026.102098_bib59","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.beem.2026.102098_bib60","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.beem.2026.102098_bib61","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.beem.2026.102098_bib62","first-page":"1737","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"386","author":"The EMPA-KIDNEY Collaborative Group","year":"2022","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.beem.2026.102098_bib63","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.beem.2026.102098_bib64","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.beem.2026.102098_bib65","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.beem.2026.102098_bib66","first-page":"951","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on inflammation and fibrosis biomarkers in CKD","volume":"13","author":"Dekkers","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.beem.2026.102098_bib67","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE\u2013TIMI 58 randomized trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2026.102098_bib68","first-page":"S1","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","author":"KDIGO Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.beem.2026.102098_bib69","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.beem.2026.102098_bib70","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and nonsteroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.beem.2026.102098_bib71","first-page":"2419","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: ARTS-DN trial","volume":"26","author":"Bakris","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.beem.2026.102098_bib72","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: FIDELITY analysis","volume":"43","author":"Filippatos","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.beem.2026.102098_bib73","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beem.2026.102098_bib74","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2215\/CJN.0000000865","article-title":"Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE","volume":"21","author":"Agarwal","year":"2026","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.beem.2026.102098_bib75","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.beem.2026.102098_bib76","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.beem.2026.102098_bib77","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2337\/dc23-0231","article-title":"Dulaglutide and kidney function-related outcomes in type 2 diabetes: a REWIND Post Hoc analysis","volume":"46","author":"Batros","year":"2023","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.beem.2026.102098_bib78","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.beem.2026.102098_bib79","first-page":"388","article-title":"Effects of GLP-1 on renal physiology and pathophysiology","volume":"10","author":"Skov","year":"2014","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"10.1016\/j.beem.2026.102098_bib80","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2026.102098_bib81","first-page":"xxxx","article-title":"Effects of semaglutide on kidney outcomes in patients with type 2 diabetes and chronic kidney disease (FLOW): a randomized, double-blind, placebo-controlled trial","volume":"390","author":"Mann","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.beem.2026.102098_bib82","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA consensus conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"issue":"9784","key":"10.1016\/j.beem.2026.102098_bib83","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (SHARP)","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"9435","key":"10.1016\/j.beem.2026.102098_bib84","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes (CARDS)","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.beem.2026.102098_bib85","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis (4D)","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.beem.2026.102098_bib86","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis (AURORA)","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.beem.2026.102098_bib87","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: a systematic review and meta-analysis","volume":"60","author":"Jun","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.beem.2026.102098_bib88","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridaemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2026.102098_bib89","article-title":"Prevalence and associated factors for non-alcoholic fatty liver disease among adults in the South Asian Region: a meta-analysis","volume":"15","author":"Niriella","year":"2023","journal-title":"Lancet Reg HealthSoutheast Asia"},{"key":"10.1016\/j.beem.2026.102098_bib90","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: a systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.beem.2026.102098_bib91","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.beem.2026.102098_bib92","first-page":"505","article-title":"Statins and non-alcoholic fatty liver disease: a clinical perspective","volume":"12","author":"Athyros","year":"2014","journal-title":"Curr Vasc Pharmacol"},{"issue":"10","key":"10.1016\/j.beem.2026.102098_bib93","first-page":"E145","article-title":"Effect of sodium\u2013glucose cotransporter-2 inhibitors on fatty liver in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"48","author":"Seko","year":"2018","journal-title":"Hepatol Res"},{"issue":"9","key":"10.1016\/j.beem.2026.102098_bib94","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1093\/ndt\/gft029","article-title":"Uric acid and chronic kidney disease: which is chasing which?","volume":"28","author":"Johnson","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"26","key":"10.1016\/j.beem.2026.102098_bib95","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beem.2026.102098_bib96","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.beem.2026.102098_bib97","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1053\/j.ajkd.2015.08.028","article-title":"Metabolic acidosis of CKD: an update","volume":"67","author":"Kraut","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"563","key":"10.1016\/j.beem.2026.102098_bib98","article-title":"Microbiota effect on trimethylamine N-oxide production: from cancer to fitness\u2014a practical preventing recommendation and therapies","volume":"15","author":"Tacconi","year":"2023","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.beem.2026.102098_bib99","article-title":"Synbiotics, prebiotics and probiotics for people with chronic kidney disease","volume":"10","author":"Cooper","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.beem.2026.102098_bib100","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.kint.2023.12.003","article-title":"Mind the gap in kidney care: translating what we know into what we do","volume":"105","author":"Luyckx","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.beem.2026.102098_bib101","article-title":"Implementation of established global guidelines in the management of CKD in patients with Type 2 diabetes in Asia","author":"Agarwal","year":"2025","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X26000199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X26000199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:36:44Z","timestamp":1783381004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X26000199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1521690X26000199"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2026.102098","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation and management of metabolic-associated chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2026.102098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102098"}}